Omega Therapeutics to Participate in the Jefferies London Healthcare Conference
Omega Therapeutics (Nasdaq: OMGA), a pioneering biotechnology firm in mRNA therapeutics, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2022, at 11:30 a.m. GMT (6:30 a.m. ET). A live webcast will be available on the company's website, with an archived replay accessible for 90 days. Omega is advancing its OMEGA Epigenomic Programming™ platform, targeting gene expression to tackle diseases across various areas, including oncology and immunology.
- None.
- None.
CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 11:30 a.m. GMT (6:30 a.m. ET).
A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chat will be available on the same website for approximately 90 days.
Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The Company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers™, target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
Contacts
Investor contact:
Eva Stroynowski
Omega Therapeutics
617.949.4370
estroynowski@omegatx.com
Media contact:
Jason Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-301666519.html
SOURCE Omega Therapeutics
FAQ
What date will Omega Therapeutics participate in the Jefferies London Healthcare Conference?
What time is Omega Therapeutics' fireside chat at the conference?
Where can I watch the Omega Therapeutics fireside chat live?
How long will the archived replay of the fireside chat be available?
What is the focus of Omega Therapeutics' OMEGA Epigenomic Programming™ platform?
Which disease areas is Omega Therapeutics currently targeting?
